BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25831546)

  • 1. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
    Srivastava AK; Han C; Zhao R; Cui T; Dai Y; Mao C; Zhao W; Zhang X; Yu J; Wang QE
    Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4411-6. PubMed ID: 25831546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA polymerase eta: A potential pharmacological target for cancer therapy.
    Saha P; Mandal T; Talukdar AD; Kumar D; Kumar S; Tripathi PP; Wang QE; Srivastava AK
    J Cell Physiol; 2021 Jun; 236(6):4106-4120. PubMed ID: 33184862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
    Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
    Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumiflavin increases the sensitivity of ovarian cancer stem-like cells to cisplatin by interfering with riboflavin.
    Yang R; Wei Z; Wu S
    J Cell Mol Med; 2019 Aug; 23(8):5329-5339. PubMed ID: 31187586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.
    Albertella MR; Green CM; Lehmann AR; O'Connor MJ
    Cancer Res; 2005 Nov; 65(21):9799-806. PubMed ID: 16267001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin induces stemness in ovarian cancer.
    Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
    Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neil 1 deficiency facilitates chemoresistance through upregulation of RAD18 expression in ovarian cancer stem cells.
    Shukla D; Mandal T; Srivastava AK
    Biochem Biophys Res Commun; 2024 Jun; 712-713():149907. PubMed ID: 38636303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA polymerase eta, a key protein in translesion synthesis in human cells.
    Cruet-Hennequart S; Gallagher K; Sokòl AM; Villalan S; Prendergast AM; Carty MP
    Subcell Biochem; 2010; 50():189-209. PubMed ID: 20012583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
    Ma L; Lai D; Liu T; Cheng W; Guo L
    Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
    Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
    Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
    Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
    Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD10
    Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
    Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
    Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification of the biological characteristics of human ovarian cancer stem cells.
    Yan HC; Fang LS; Xu J; Qiu YY; Lin XM; Huang HX; Han QY
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3497-503. PubMed ID: 25491627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting translesion synthesis to facilitate the eradication of ovarian cancer stem cells by platinum-based therapy.
    Srivastava AK; Wang QE
    Mol Cell Oncol; 2016; 3(1):e1043482. PubMed ID: 27308560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
    Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
    J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.